相关临床试验
2594
269 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1895
终止
40
1.5%
招募中
416
16.0%
暂停
3
0.1%
Available
4
0.1%
撤回
24
0.9%
进行中（未招募）
61
2.4%
已完成
851
32.8%
Unknown
987
38.0%
Enrolling By Invitation
48
1.9%
尚未招募
160
6.2%
暂无批准数据
- A single-center study of 43 children with drug-resistant epilepsy found that baseline nutritional status influences ketogenic diet (KD) therapy outcomes, with 25.6% achieving ≥70% seizure reduction within 3 months. - Adequate pre-KD intake of magnesium, zinc, and vitamin E was significantly associated with ≥70% seizure reduction at 6 months, with robust odds ratios across adjusted models. - At 3 months, higher n-3/n-6 PUFA intake and adequate phosphorus were linked to better seizure control, suggesting a temporal shift in nutritional predictors during therapy. - Researchers recommend pre-KD nutritional assessment of magnesium, zinc, and vitamin E to optimize seizure control, though larger multicenter trials are needed to confirm causality.
- HistoSonics received Taiwan Food and Drug Administration (TFDA) approval for the Edison Histotripsy System, marking a significant milestone in the company's Asia-Pacific expansion. - The Edison System uses non-invasive, non-thermal focused ultrasound to mechanically liquefy and destroy targeted liver tumors without surgery or radiation. - National Taiwan University Hospital served as the first installation site, achieving one of the fastest rates of clinical adoption for histotripsy globally under research protocols. - The approval builds on prior FDA clearance (October 2023) and CE Mark authorization in Europe, where the #HOPE4LIVER pivotal trial demonstrated 90% local tumor control at 12 months.
- Taiwan's National Health Insurance Administration approved coverage for a NT$100 million gene therapy treating aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder affecting infants. - The therapy, originally developed by National Taiwan University Hospital in 2007, showed remarkable results with 80% of trial patients able to sit up and 40% achieving independent walking after early treatment. - The decision sparked controversy over healthcare resource allocation, as physicians argue other rare diseases affecting more patients receive less comprehensive coverage despite lower costs. - NHIA estimates treating 13 patients in the first year will cost NT$1.3 billion, with ongoing annual costs of NT$500 million for five additional patients yearly.
- Gene Solutions has launched SPOT-MAS, an AI-powered multi-cancer early detection platform in Taiwan, integrating multi-omics cell-free DNA analysis to bridge gaps in traditional cancer screening. - The technology analyzes genetic, epigenetic, and fragmentomic features using AI algorithms to enhance early detection accuracy and predict tumor location more precisely than single biomarker approaches. - Taiwan medical experts emphasize the urgent clinical need, noting that early cancer detection can result in five-year survival rates several times higher than late-stage detection. - The launch represents a significant step toward making multi-cancer screening accessible beyond premium healthcare, with plans for cross-sector collaboration to establish comprehensive cancer prevention frameworks.
- A retrospective study of over 1.2 million Taiwanese children found that longer-term atropine prescription for myopia control was associated with increased risk of ocular complications, though this risk may be confounded by myopia severity. - Children with myopia had a 49% higher risk of developing cataracts, glaucoma, and maculopathy compared to non-myopic children, with no overall difference between atropine users and non-users. - The study revealed a paradox where duration of atropine use showed increased risk, but cumulative dosing showed no association with complications, suggesting myopia severity rather than atropine itself drives the risk. - Researchers emphasized the need for continued monitoring of children receiving atropine treatment and called for future studies to address the study's limitations before drawing definitive conclusions.
• JelloX Biotech's 3D pathology technology identified significantly more HER2-low and HER2-ultralow breast tumors compared to conventional diagnostic methods in a study with National Taiwan University Hospital. • Over 50% of analyzed breast cancer cases showed diagnostic discrepancies when re-evaluated with 3D pathology, with 66.7% of initially HER2-null patients reclassified as HER2-expressing. • The improved detection sensitivity could expand treatment eligibility for Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that has shown robust efficacy in HER2-low and HER2-ultralow metastatic breast cancer.
- Ainos has secured TFDA approval for a clinical trial of VELDONA in HIV-related oral warts and IRB clearance for a Sjögren's Syndrome study, targeting two rare diseases with significant unmet needs. - The company is implementing a bridging strategy between Taiwan and US regulatory agencies that could accelerate market entry through a harmonized approval process for their next-generation oral interferon formulation. - VELDONA offers a non-invasive alternative to injectable interferons, with previous trials showing significant improvement in Sjögren's Syndrome symptoms and potential in the estimated $500-700 million global market for HIV-related HPV manifestations.
- Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening. - A recently published study demonstrated that Nu.Q® Cancer test can accurately detect 21 different cancer types with high specificity, positioning it as a potential standalone pan-cancer test or complement to existing liquid biopsy technologies. - The company is pursuing multiple licensing agreements with diagnostic and liquid biopsy companies in 2025, targeting the $20 billion liquid biopsy market with a test that can run on existing automated platforms worldwide.
- Taiwanese researchers from NTHU and NHRI have developed a breakthrough small-molecule drug that treats chronic intestinal inflammation by blocking PANX1 ion channels in intestinal cells. - The new drug addresses a significant medical need, with IBD affecting 5% of Western populations and showing increasing prevalence in Taiwan, where ulcerative colitis affects 19.6 per 100,000 people. - The research team successfully modified the drug's molecular structure to eliminate previous liver toxicity issues while enhancing its efficacy, potentially extending its application to other inflammatory conditions.
